GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Isofol Medical AB (OSTO:ISOFOL) » Definitions » Net Income Including Noncontrolling Interests

Isofol Medical AB (OSTO:ISOFOL) Net Income Including Noncontrolling Interests : kr-31.16 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Isofol Medical AB Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Isofol Medical AB's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2024 was kr-8.48 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 was kr-31.16 Mil.

Isofol Medical AB Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Isofol Medical AB's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Isofol Medical AB Net Income Including Noncontrolling Interests Chart

Isofol Medical AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only -161.58 -188.99 -200.25 -159.79 -37.07

Isofol Medical AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.39 -7.51 -6.26 -8.91 -8.48

Isofol Medical AB Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-31.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Isofol Medical AB Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Isofol Medical AB's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Isofol Medical AB (OSTO:ISOFOL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Isofol Medical AB (OSTO:ISOFOL) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
OSTO:SPRINT OSTO:ELIC OSTO:ALZ OSTO:BIOVIC B OSTO:NXTCL XSAT:CESSA OSTO:ACE OSTO:LIPUM OSTO:SIMRIS B OSTO:ZICC OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
5IU:Germany
Address
Arvid Wallgrens Backe 20, Biotech Center, Gothenburg, SWE, SE-413 46
Website
http://www.isofol.se
Isofol Medical AB is a pharmaceutical company. It is a manufacturer of folate-based therapies. The company's drug candidate Modufolin enhances the effect of the current chemotherapy treatment for patients treated for colorectal cancer. Its products are used to increase efficacy and reduce the side effects of antimetabolite cancer treatment.

Isofol Medical AB (OSTO:ISOFOL) Headlines

No Headlines